"Pyrroles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.
| Descriptor ID |
D011758
|
| MeSH Number(s) |
D03.383.129.578
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrroles".
Below are MeSH descriptors whose meaning is more specific than "Pyrroles".
This graph shows the total number of publications written about "Pyrroles" by people in this website by year, and whether "Pyrroles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrroles" by people in Profiles.
-
Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor. Pediatr Pulmonol. 2024 Jul; 59(7):2051-2054.
-
Recycling Polymeric Solid Wastes for Energy-Efficient Water Purification, Organic Distillation, and Oil Spill Cleanup. Small. 2021 11; 17(46):e2102459.
-
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer Chemother Pharmacol. 2021 05; 87(5):689-700.
-
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Adv Ther. 2021 01; 38(1):350-365.
-
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
-
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621.
-
Tofacitinib for the treatment of lichen planopilaris: A case series. Dermatol Ther. 2018 11; 31(6):e12656.
-
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.
-
Molecular docking studies of 3-bromopyruvate and its derivatives to metabolic regulatory enzymes: Implication in designing of novel anticancer therapeutic strategies. PLoS One. 2017; 12(5):e0176403.
-
Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Bioorg Med Chem Lett. 2017 04 01; 27(7):1602-1607.